` ECOR (electroCore, Inc.) vs S&P 500 Comparison - Alpha Spread

ECOR
vs
S&P 500

Over the past 12 months, ECOR has significantly outperformed S&P 500, delivering a return of 28% compared to the S&P 500's 8% growth.

Stocks Performance
ECOR vs S&P 500

Loading
ECOR
S&P 500
Add Stock

Performance Gap
ECOR vs S&P 500

Loading
ECOR
S&P 500
Difference

Performance By Year
ECOR vs S&P 500

Loading
ECOR
S&P 500
Add Stock

Competitors Performance
electroCore, Inc. vs Peers

electroCore, Inc.
Glance View

Market Cap
52.3m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.41 USD
Undervaluation 56%
Intrinsic Value
Price
Back to Top